{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T19:42:58Z","timestamp":1793475778977,"version":"4.5.0"},"reference-count":44,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T00:00:00Z","timestamp":1652400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Technology"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:p>\n                    Objective: To review the efficacy, safety, and role of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide for chronic weight management. Data Sources: A literature search of PubMed\/MEDLINE and Google Scholar was performed using the search terms: semaglutide 2.4, weight, and obesity. Ongoing studies of semaglutide were identified utilizing clinicaltrials.gov. Study Selection and Data Extraction: All English-language articles evaluating the efficacy and safety of semaglutide 2.4 mg for weight management in humans were included. Data Synthesis: Once-weekly injectable semaglutide 2.4 mg is indicated as an adjunct to a reduced-calorie diet and increased exercise for chronic weight management in adults with a body mass index (BMI) \u226530 kg\/m\n                    <jats:sup>2<\/jats:sup>\n                    or \u226527 kg\/m\n                    <jats:sup>2<\/jats:sup>\n                    with at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or dyslipidemia. Semaglutide 2.4 mg has consistently demonstrated clinically significant weight loss across all phase 3 STEP (semaglutide treatment effect in people with obesity) trials, and long-term efficacy and safety have been confirmed for up to 2 years. Gastrointestinal side effects were the most frequently reported side effects, including nausea, vomiting, constipation, and diarrhea. Safety data for semaglutide 2.4 mg were consistent with that reported previously for the GLP-1 receptor agonist class. Conclusions: Semaglutide 2.4 mg is a highly efficacious agent for weight management, with a safety profile similar to that of other GLP-1 receptor agonists. It is a feasible option for chronic weight management, with data for up to 2 years. It is currently the only once-weekly weight loss medication, although cost may limit its utilization.\n                  <\/jats:p>","DOI":"10.1177\/87551225221092681","type":"journal-article","created":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T20:01:02Z","timestamp":1652904062000},"page":"239-246","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":50,"title":["Once-Weekly Semaglutide for Weight Management: A Clinical Review"],"prefix":"10.1177","volume":"38","author":[{"given":"Abby","family":"Fornes","sequence":"first","affiliation":[{"name":"Bernard J. Dunn School of Pharmacy, Shenandoah University, Fairfax, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4037-1618","authenticated-orcid":false,"given":"Jamie","family":"Huff","sequence":"additional","affiliation":[{"name":"Bernard J. Dunn School of Pharmacy, Shenandoah University, Winchester, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6828-907X","authenticated-orcid":false,"given":"Roger Iain","family":"Pritchard","sequence":"additional","affiliation":[{"name":"Bernard J. Dunn School of Pharmacy, Shenandoah University, Winchester, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miranda","family":"Godfrey","sequence":"additional","affiliation":[{"name":"Bernard J. Dunn School of Pharmacy, Shenandoah University, Winchester, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,5,13]]},"reference":[{"key":"bibr1-87551225221092681","unstructured":"World Health Organization. Obesity and overweight. Accessed August 27, 2021. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight."},{"key":"bibr2-87551225221092681","doi-asserted-by":"publisher","DOI":"10.1172\/JCI10842"},{"key":"bibr3-87551225221092681","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.1995.75.3.473"},{"key":"bibr4-87551225221092681","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000437739.71477.ee"},{"key":"bibr5-87551225221092681","doi-asserted-by":"publisher","DOI":"10.4158\/EP161365.GL"},{"key":"bibr6-87551225221092681","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30013-X"},{"key":"bibr7-87551225221092681","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30092-X"},{"key":"bibr8-87551225221092681","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-0417"},{"key":"bibr9-87551225221092681","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30085-2"},{"key":"bibr10-87551225221092681","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-00070"},{"key":"bibr11-87551225221092681","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141"},{"key":"bibr12-87551225221092681","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30024-X"},{"key":"bibr13-87551225221092681","unstructured":"Wegovy [package insert]. Plainsboro, NJ: Novo Nordisk Inc; 2021. https:\/\/www.novo-pi.com\/wegovy.pdf."},{"key":"bibr14-87551225221092681","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69705-5"},{"key":"bibr15-87551225221092681","doi-asserted-by":"publisher","DOI":"10.2147\/dmsott.s6816"},{"key":"bibr16-87551225221092681","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183"},{"key":"bibr17-87551225221092681","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00213-0"},{"key":"bibr18-87551225221092681","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.1831"},{"key":"bibr19-87551225221092681","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.3224"},{"key":"bibr20-87551225221092681","volume-title":"Paper presented at the 39th Annual Meeting of The Obesity Society (TOS) held at ObesityWeek\u00ae","author":"Garvey WT"},{"key":"bibr21-87551225221092681","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.23619"},{"key":"bibr22-87551225221092681","unstructured":"U.S. National Library of Medicine. ClinicalTrials.gov. Semaglutide effects on heart disease and stroke in patients with overweight or obesity (SELECT). Published July 2, 2018. Accessed July 27, 2021. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03574597."},{"key":"bibr23-87551225221092681","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31773-2"},{"key":"bibr24-87551225221092681","unstructured":"Saxenda [package insert]. Plainsboro, NJ: Novo Nordisk Inc; 2018. Accessed April 4, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/206321s007lbl.pdf."},{"key":"bibr25-87551225221092681","unstructured":"Qsymia [package insert]. Campbell, CA: Vivus; 2020. Accessed April 4, 2022. https:\/\/qsymia.com\/patient\/include\/media\/pdf\/prescribing-information.pdf."},{"key":"bibr26-87551225221092681","unstructured":"Contrave [package insert]. Morristown, NJ: Nalpropion Pharmaceuticals LLC; 2021. Accessed April 4, 2022. https:\/\/contravehcp.com\/wp-content\/uploads\/Contrave_PI_MedGuide.pdf."},{"key":"bibr27-87551225221092681","unstructured":"Xenical [package insert]. South San Francisco, CA: Genentech USA; 2012. Accessed April 4, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/020766s029lbl.pdf."},{"key":"bibr28-87551225221092681","unstructured":"Adipex-P [package insert]. Sellersville, PA: Teva Pharmaceuticals USA; 2012. Accessed April 4, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/085128s065lbl.pdf."},{"key":"bibr29-87551225221092681","unstructured":"Active Ingredient: Semaglutide. RED BOOK Online. IBM Micromedex [database online]. Truven Health Analytics\/IBM Watson Health; 2021. Accessed September 1, 2021. https:\/\/www.micromedexsolutions.com."},{"key":"bibr30-87551225221092681","unstructured":"Active Ingredient: Liraglutide. RED BOOK Online. IBM Micromedex [database online]. Truven Health Analytics\/IBM Watson Health; 2021. Accessed September 1, 2021. https:\/\/www.micromedexsolutions.com."},{"key":"bibr31-87551225221092681","unstructured":"Active Ingredient: Phentermine HCl\/Topiramate. RED BOOK Online. IBM Micromedex [database online]. Truven Health Analytics\/IBM Watson Health; 2021. Accessed September 1, 2021. https:\/\/www.micromedexsolutions.com."},{"key":"bibr32-87551225221092681","unstructured":"Active Ingredient: Bupropion HCl\/Naltrexone. RED BOOK Online. IBM Micromedex [database online]. Truven Health Analytics\/IBM Watson Health; 2021. Accessed September 1, 2021. https:\/\/www.micromedexsolutions.com."},{"key":"bibr33-87551225221092681","unstructured":"Active Ingredient: Orlistat. RED BOOK Online. IBM Micromedex [database online]. Truven Health Analytics\/IBM Watson Health; 2021. Accessed September 1, 2021. https:\/\/www.micromedexsolutions.com."},{"key":"bibr34-87551225221092681","unstructured":"Active Ingredient: Phentermine HCl. RED BOOK Online. IBM Micromedex [database online]. Truven Health Analytics\/IBM Watson Health; 2021. Accessed September 1, 2021. https:\/\/www.micromedexsolutions.com."},{"key":"bibr35-87551225221092681","doi-asserted-by":"publisher","DOI":"10.1002\/oby.20584"},{"key":"bibr36-87551225221092681","unstructured":"Ozempic [package insert]. Plainsboro, NJ: Novo Nordisk Inc; 2021."},{"key":"bibr37-87551225221092681","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.116.7.874"},{"key":"bibr38-87551225221092681","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14280"},{"key":"bibr39-87551225221092681","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00756-2"},{"key":"bibr40-87551225221092681","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-017-0532-6"},{"key":"bibr41-87551225221092681","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.14060"},{"key":"bibr42-87551225221092681","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-021-01189-6"},{"key":"bibr43-87551225221092681","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-S008"},{"key":"bibr44-87551225221092681","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2016.2317"}],"container-title":["Journal of Pharmacy Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/87551225221092681","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/87551225221092681","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/87551225221092681","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T02:30:59Z","timestamp":1777602659000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/87551225221092681"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,13]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.1177\/87551225221092681"],"URL":"https:\/\/doi.org\/10.1177\/87551225221092681","relation":{},"ISSN":["8755-1225","1549-4810"],"issn-type":[{"value":"8755-1225","type":"print"},{"value":"1549-4810","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,13]]}}}